Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266155 | 0.98 | LTA4H (0.62) | LTA4HHRH3 | |
| SCHEMBL9097701 | 0.95 | LTA4H (0.66) | LTA4HHRH3MEN1ALDH1A1MAPT | |
| SCHEMBL211606 | 0.90 | LTA4H (0.77) | LTA4HMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL9122265 | 0.90 | LTA4H (0.77) | LTA4HMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5331925 | 0.89 | HRH3 (0.67) | LTA4HHRH3MEN1ALDH1A1MAPT | |
| SCHEMBL22266165 | 0.88 | LTA4H (0.58) | LTA4HHRH3MEN1ALDH1A1MAPT | |
| SCHEMBL22266156 | 0.87 | LTA4H (0.65) | LTA4HHRH3MEN1ALDH1A1MAPT | |
| SCHEMBL491672 | 0.84 | HRH3 (0.79) | LTA4HHRH3ALDH1A1SMN1; SMN2HRH1 | |
| SCHEMBL28285428 | 0.84 | HRH3 (0.70) | HRH3MEN1KMT2AHRH2HRH1 | |
| SCHEMBL5455464 | 0.84 | LTA4H (0.69) | LTA4HHRH3ALDH1A1SMN1; SMN2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-8796264-B2 | 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-08-05 | — | — | US | disclosed |
| EP-2640712-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2012066518-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2012-05-24 | — | — | WO | disclosed |
| EP-1099692-B1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6737425-B1 | SUCH AS 1-((4-CYANO-5-METHYL-4-PHENYL)HEXYL)-4-(2-(4-FLUORO -PHENOXY)ETHYL)PIPERAZINE; NERVE SELECTIVE CALCIUM ANTAGONISTS | EISAI CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| EP-1099692-A1 | N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2001-05-16 | — | — | EP | disclosed |
| US-4582833-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4562189-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1985-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | BPGM, TBC1D5, TBC1D15 | LTA4H 47/4885HRH3 1563/4885MEN1 4570/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | LTA4H 3562/4885HRH3 3690/4885MEN1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.